Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | GC | P02774 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297400 | 1.00 | VDR (0.41) | VDRCYP19A1MAPTSREBF1SMN1; SMN2 | |
| SCHEMBL3258798 | 1.00 | VDR (0.41) | VDRCYP19A1MAPTSREBF1SMN1; SMN2 | |
| SCHEMBL13588190 | 0.89 | VDR (0.36) | VDRCYP19A1MAPTSREBF1SMN1; SMN2 | |
| SCHEMBL13410629 | 0.89 | VDR (0.36) | VDRCYP19A1MAPTSREBF1SMN1; SMN2 | |
| SCHEMBL13875473 | 0.86 | VDR (0.33) | VDRCYP19A1 | |
| SCHEMBL13392980 | 0.85 | VDR (0.34) | VDRCYP19A1MAPTSREBF1SMN1; SMN2 | |
| SCHEMBL3300947 | 0.85 | VDR (0.34) | VDRCYP19A1MAPTSREBF1SMN1; SMN2 | |
| SCHEMBL3260426 | 0.85 | VDR (0.34) | VDRCYP19A1MAPTSREBF1SMN1; SMN2 | |
| SCHEMBL13392819 | 0.85 | VDR (0.34) | VDRCYP19A1MAPTSREBF1SMN1; SMN2 | |
| SCHEMBL3260431 | 0.85 | VDR (0.34) | VDRCYP19A1MAPTSREBF1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| EP-2073814-A2 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | Bioxell S.p.a. (IT) | 2009-07-01 | — | — | EP | disclosed |
| EP-2063899-A2 | USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OF ADHESIONS | Bioxell S.p.a. (IT) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099140-A1 | 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof | BIOXELL S.P.A. (IT) | 2009-04-16 | — | — | US | disclosed |
| US-20090099140-A1 | 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof | BIOXELL S.P.A. (IT) | 2009-04-16 | — | — | US | disclosed |
| WO-2008043857-A2 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL SPA (IT) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008034908-A2 | USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OF ADHESIONS | BIOXELL SPA (IT) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008034908-A2 | USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OF ADHESIONS | BIOXELL SPA (IT) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | CYP27B1, CYP2R1, SHBG | VDR 5/4885CYP19A1 25/4885MAPT 4547/4885 |
| US-20100093675-A1 | NOVEL METHOD | GC, VDR, CYP24A1 | VDR 2/4885CYP19A1 2283/4885MAPT 4570/4885 |
| US-20090099140-A1 | 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof | VDR, CYP24A1, CYP2R1 | VDR 1/4885CYP19A1 141/4885MAPT 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.